← All research

Semaglutide Side Effects: 10 Questions, Answered From the Trials

Last verified May 2026 · 10 questions · 15 PubMed citations

Questions taken from r/Semaglutide, r/WegovyWeightLoss, r/Ozempic

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

Side-effect questions get answered badly in both directions — dismissed as anxiety, or inflated into a reason to quit a drug that was working. This page tries for the useful middle: what the trials measured, how often, how long it lasted, and what the escalation signal is. ⚠ Rates come from the randomized trials wherever one exists; where the only evidence is adverse-event reporting, which cannot establish cause, it is labeled as such. Each answer links to the papers it rests on, with the full reference list at the foot. ⛔ Nothing here is a substitute for telling your prescriber what is actually happening to you.

Questions and answers

Q1.Does the nausea ever stop?

★ For most people, yes — it crests while the dose is climbing and settles once you hold. STEP-1 recorded nausea in 44% on semaglutide against 16% on placebo across 68 weeks, but the episodes were mostly mild to moderate and clustered around the four-weekly step-ups rather than running the whole trial. ★ The number that reframes it: only about 4-7% quit over stomach side effects, against 2-3% on placebo. The overwhelming majority rode it out. ⚠ The ladder climbs 0.25 to 0.5, then 1.0, 1.7 and 2.4 mg with a month at each rung, and it is built at that pace for exactly this reason — holding a rough step for an extra month instead of climbing on schedule is a normal thing to ask for. ⛔ What is not waiting-it-out territory: severe abdominal pain that persists, vomiting to the point of dehydration, or gallbladder symptoms. Those are phone calls, not forum posts.

Source thread ↗PMID 33567185

Q2.Why do the burps smell like eggs?

★ Because food is sitting in your stomach longer than it used to. Semaglutide slows gastric emptying — roughly 30% less emptied in the first hour after a meal — so a protein- or fat-heavy meal lingers, and gut bacteria break the sulfur-bearing amino acids in it down to hydrogen sulfide. That is the rotten-egg smell, and it is a digestion-timing problem rather than a sign of damage. ⚠ STEP-1 reported indigestion, burping and reflux more often on semaglutide than placebo, which is the same slowed-transit story from a different angle. ★ The triggers people converge on are consistent: large late meals, red meat, eggs, cruciferous vegetables. Smaller portions, eating earlier, and staying upright afterward are the levers. ⛔ One pattern is different and matters: severe upper-abdominal pain boring through to the back is not a burping problem. That is a same-day call.

Source thread ↗PMID 28941314PMID 33567185

Q3.What actually helps the constipation?

★ Ordinary constipation care, because the cause is mostly mechanical. STEP-1 reported it in about 24% on semaglutide against 11% on placebo. Slower emptying plus genuinely less food means less bulk and less water moving through. ★ What people land on maps onto standard advice: 80-100 oz of fluid daily, a soluble fiber such as psyllium, a magnesium salt at bedtime, and walking. Senna and its relatives suit an occasional bad week, not every week. ⛔ There is a reason not to simply tolerate it indefinitely: a 2023 JAMA analysis found GLP-1 agonists carried roughly four times the bowel-obstruction risk of bupropion-naltrexone, though the absolute rate stayed low. ⚠ So the escalation signal is specific — several days without a movement, plus pain and vomiting, is an obstruction question and needs a prompt call rather than another dose of magnesium.

Source thread ↗PMID 33567185PMID 37796527

Q4.Is the gallbladder risk real?

⚠ Yes, and the evidence is consistent enough that it is worth knowing the warning signs before you need them. A 2022 meta-analysis pooling 76 randomized trials and more than 100,000 patients put gallbladder and biliary disease about 37% above comparator on GLP-1 agonists, concentrated at the higher doses and longer durations used for weight loss. In STEP-1 itself, gallbladder events hit 2.6% on semaglutide against 1.2% on placebo. ★ Part of that is not the drug at all: losing weight quickly is an established gallstone trigger by itself, so the drug and the result it produces are hard to separate. The Wegovy label carries an acute gallbladder disease warning regardless. ⛔ In plain terms, most people never have a gallbladder problem, and the risk is still genuinely raised. The pattern to escalate is pain under the right ribs after fatty meals, with nausea or fever.

Source thread ↗PMID 35344001PMID 33567185

Q5.Am I losing muscle as well as fat?

★ Some, and that is true of any substantial weight loss rather than something semaglutide does to you. The DXA substudy inside STEP-1 found that in people who lost about 15% of body weight, roughly 39% of what came off was lean tissue and 61% fat — and because so much fat went, the proportion of the body that was fat still fell. ⚠ That ratio is broadly what diet-only weight loss produces, which is the useful comparison: the drug is not stripping muscle in some distinctive way. ★ The countermeasures are cheap, evidenced and entirely within your control — protein in the region of 1.2-1.6 g per kg of body weight daily, resistance training two or three times a week, and no long runs of very low intake. ⛔ The people who lose a worse share of lean tissue are reliably the ones eating little protein, lifting nothing, and dropping weight fast. All three are choices.

Source thread ↗PMID 33567185PMID 38710803

Q6.Is the hair loss permanent?

★ Usually not. What is described fits telogen effluvium — the diffuse shedding that follows rapid weight loss and reverses once weight and intake stabilize. A 2025 systematic review of hair loss on GLP-1 agonists reached that conclusion, and telogen effluvium characteristically recovers. ⚠ Be careful how strong you let the evidence sound, though. The signal comes largely from adverse-event reporting: a disproportionality analysis of 2022-23 FAERS reports found alopecia reported significantly more often for semaglutide and tirzepatide than for comparator drugs, and a VigiBase study found the same while stressing that absolute risk per patient stayed low. ⛔ Reporting databases cannot establish cause — they measure what people report, which is shaped by what people have heard about. ★ The levers worth pulling anyway: enough protein, iron, zinc, vitamin D and B12, and a slower rate of loss. Patchy or persistent shedding is a dermatology question, not a nutrition one.

Source thread ↗PMID 38925559PMID 41111833PMID 39264502

Q7.Why can't I sleep?

⚠ Honestly, this one is weakly evidenced, and it is worth saying so. Insomnia is not among semaglutide's prominent labeled adverse events, and no trial was built to measure it — but it recurs in patient reports consistently enough to take seriously rather than dismiss. ★ Three mechanisms have been proposed and each is plausible: rapid weight loss itself disturbs sleep architecture, a much smaller evening intake can wake you early, and the small mean heart-rate rise of a few beats per minute seen in the trials is perceptible to some people. None of that is established as the cause of your particular bad night. ★ What people report helping is cheap to try — dose in the morning, finish eating about three hours before bed, cut afternoon caffeine, and do not make the last meal of the day a purely protein one. ⚠ If it persists past the first month or two at a steady dose, dose timing or a temporary hold is a reasonable conversation to have.

Source thread ↗PMID 33567185PMID 27633186

Q8.Does it cause depression or suicidal thoughts?

⚠ The best evidence says no, and the contested evidence deserves stating rather than burying. In STEP-1, depression and suicidal-behavior events were rare and comparable between drug and placebo — though people with active suicidal ideation were excluded at entry, which limits what that shows. ★ The largest real-world study, covering more than 240,000 people in Nature Medicine in 2024, found semaglutide associated with a LOWER risk of suicidal ideation than other weight or diabetes drugs. ⚠ Against that, adverse-event reporting analyses have flagged disproportionate suicidality reports for this drug class and triggered regulatory review; those databases cannot separate the drug from the people taking it, and the disagreement is genuine. ⛔ Mechanism matters here too: losing a great deal of weight quickly changes intake, routine and self-image, and mood can move without the molecule causing it. Anyone with active depression, an eating-disorder history or prior suicidality should go in with a monitoring plan agreed in advance.

Source thread ↗PMID 33567185PMID 38182782PMID 38087976PMID 39433133

Q9.Can it affect my vision?

⚠ Mostly in people who already have diabetic eye disease, and the mechanism is the blood-sugar drop rather than the drug touching the eye. SUSTAIN-6 found retinopathy complications in 3.0% on semaglutide against 1.8% on placebo over 104 weeks — concentrated in participants who already had retinopathy and whose HbA1c fell fast. ★ A pre-specified analysis tied the excess to the size and speed of that glycemic improvement, which is a pattern known for decades from intensive insulin treatment. In other words it is the correction, not the corrector. ⚠ FOCUS is the trial built specifically to settle the semaglutide-and-retinopathy question, and reviews continue to track it. ★ Among people who do not have diabetes — the STEP obesity trials included — nothing about retinopathy was flagged. Brief blurring when starting can also be plain dehydration or rapid weight change. ⛔ Persistent blurring, new floaters or eye pain is an eye-doctor appointment, not a wait-and-see.

Source thread ↗PMID 27633186PMID 29178519PMID 40586870

Q10.Why does my thyroid medication feel different?

⚠ Two things change at once, and they push your levels in opposite directions — which is exactly why this needs measuring rather than predicting. First, absorption: the label warns that delayed gastric emptying can alter uptake of oral drugs taken alongside it, and levothyroxine is the textbook case because it needs an empty stomach and a narrow window to absorb reliably. Less absorbed pushes TSH up. ⛔ Second, the weight loss itself lowers how much thyroid hormone your body needs, and an unchanged dose then becomes relatively larger — which pushes TSH down. ★ So there is no single direction to expect, and anyone telling you which way it will go is guessing. Recheck TSH six to twelve weeks after starting, and again after any meaningful weight change, and let the number decide. ⚠ For scale on the weight side: STEP-1 averaged 14.9% loss at 68 weeks on 2.4 mg, which is more than enough to move a dose requirement.

Source thread ↗PMID 29915923PMID 33567185PMID 27633186

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  2. 2.Marso SP, Bain SC, Consoli A, et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med. 2016. PMID: 27633186.
  3. 3.Hjerpsted JB, Flint A, Brooks A, et al Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity Diabetes Obes Metab. 2018. PMID: 28941314.
  4. 4.Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss JAMA. 2023. PMID: 37796527.
  5. 5.He L, Wang J, Ping F, et al Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials JAMA Intern Med. 2022. PMID: 35344001.
  6. 6.Henney AE, Wilding JPH, Alam U, Cuthbertson DJ Obesity pharmacotherapy in older adults: a narrative review of evidence Int J Obes (Lond). 2025. PMID: 38710803.
  7. 7.Godfrey H, Leibovit-Reiben Z, Jedlowski P, et al Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023 J Eur Acad Dermatol Venereol. 2025. PMID: 38925559.
  8. 8.Alsuwailem OA, Alanazi R, Almutairi HM, et al Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review Cureus. 2025. PMID: 41111833.
  9. 9.Nakhla M, Nair A, Balani P, et al Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study Cardiovasc Drugs Ther. 2025. PMID: 39264502.
  10. 10.Wang W, Volkow ND, Berger NA, et al Association of semaglutide with risk of suicidal ideation in a real-world cohort Nat Med. 2024. PMID: 38182782.
  11. 11.McIntyre RS, Mansur RB, Rosenblat JD, et al The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS) Expert Opin Drug Saf. 2024. PMID: 38087976.
  12. 12.McIntyre RS, Mansur RB, Rosenblat JD, et al Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase) J Affect Disord. 2025. PMID: 39433133.
  13. 13.Vilsboll T, Bain SC, Leiter LA, et al Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy Diabetes Obes Metab. 2018. PMID: 29178519.
  14. 14.Vujosevic S, Toma C, Ferrulli A, et al New generation agents for glycemic control and diabetic retinopathy progression: what we need to know? Acta Diabetol. 2025. PMID: 40586870.
  15. 15.Hall S, Isaacs D, Clements JN Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist Clin Pharmacokinet. 2018. PMID: 29915923.

Questions are paraphrased from public forum threads and linked to their source where one was recorded. Answers summarize published trial data and FDA labeling. This is not medical advice, and no part of it replaces the judgment of whoever prescribes for you.